Blogging elf Maxine Vaccine pays tribute to the ABPI, looks forward to the office party, and asks Pf readers a crucial question about the future.
Maxine’s attitude got her in trouble again. It must be Thursday.
A mildly snarky comment about the ABPI and its ‘the honeymoon is over’ stance on value-based pricing, and look what happens – Pf gets an e-mail from Stephen Whitehead, Chief Executive of the pharma industry’s trade association. Most shaming of all, it wasn’t a snarky response. It was a reasonable and sensible response explaining that the ABPI has always regarded the VBP concept as complex and has tried to ensure that, if it becomes the UK pharma sector’s currency, it is not devalued.
Which left your humble correspondent looking immature and shamed. Which hasn’t happened since the morning after the last office Xmas party. More about that later.
Meanwhile, I wanted to tell Stephen Whitehead – whose role as the industry’s voice I praised a few months back – that I apologise for any offence caused. It’s part of my role to voice objections that might arise in the mind of the average pharmaceutical sales professional and require an answer. And as my manager will tell you, ‘average’ is very much the word – indeed, she commented at the last staff Xmas party (of which more later) that ‘average’ was more aspirational than descriptive – in my case.
By way of reparation, and to show that I do read the ABPI press releases, here’s a short verse celebrating the Association’s hard-working and boat-rocking leadership:
Stephen Whitehead, the industry’s voice,
Said patients should have far more choice –
But the strictures of QIPP
Were a hole in the ship
Though the DH was chanting ‘Rejoice!’
Remember, this is meant to be an interactive blog. We’re keen to read your feedback on the issues raised here. Please send your comments to the Pf editor, John Pinching, at email@example.com with the subject heading ‘WTF is that Maxine talking about?’ It’s already a substantial file, as my line manager at Munchkin Pharma can attest.
In particular, we want your feedback on one of the key questions that any pharmaceutical sales professional will need to consider in 2013 as we emerge from winter into spring: Would you date a colleague?
To address the tangled theme of office romance in the issue of Pf that will be in your otherwise empty hands on Valentine’s Day, the journal called on its most creative and insightful journalist. But she was not available and the second choice was busy with NHS reform and the third choice was drunk, so they tried a few other options (including the caretaker) and finally, in desperation, called me.
So: assuming you had some time on your hands and were free (or could arrange to be on a timeshare basis), would you engage in a ‘special project partnership’ with someone from your industry, your company, and your team? Would that be the perfect prescription or a formula for disaster? Would you sell each other a vision of happiness or down the river?
Please give it some thought while munching mince pies and imbibing sweet sherry like the diabetes crisis was still a century away. Then e-mail the Pf editor (see above) with your verdict and the reason why. Thank you!
(If you work with me, there’s no need to reply. I know the answer, and I know why. It has to do with the office Xmas party. But I’m on a word limit here and there’s no space to explain.)
Have a restful Yuletide break – and look after your elf.